anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third \& final call for that day will be placed at 11:00am.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: suppository has eucalimin 0.045-0.055; chicken fat 0.068-0.084, and solid fat of type A or vitepsol as a base. Eucalimin is used as powder (dispersity is 0.5-1 mcm) that is mixed preliminary with chicken fat at ratio 1:1.5 at 36-38 C for 10-15 min. Then the obtained mixture is added to base at 36-38 C at intensive stirring for 5 min and ready mass is poured in forms. New medicinal composition of suppository shows antibacterial, antiviral and antiinflammatory action and does not cause by-side effect on human organism. EFFECT: enhanced therapeutic effect. 4 cl, 8 tbl
The prevalence of smoking and smoking-related illness is disproportionately higher among people experiencing chronic homelessness than among people in the general population. Unfortunately, smoking cessation treatment does not reach or engage the overwhelming majority of smokers experiencing chronic homelessness, and smoking-related harm persists even after people are housed. There have therefore been calls for more flexible and client-centered approaches tailored to this population's needs. In response, we are proposing a randomized controlled trial (RCT) of Harm-Reduction for Tobacco Smoking with support of Tobacco-Replacing Electronic Nicotine Delivery Systems (HaRTS-TRENDS) as an innovative, empirically informed, and client-driven alternative to traditional smoking cessation treatment. To maximize its efficacy, the 4-session, individual HaRTS-TRENDS was collaboratively designed with a community advisory board made up of researchers, people with lived experience of chronic homelessness and smoking, and staff and management at a nonprofit, community-based housing agency. HaRTS-TRENDS entails the provision of electronic nicotine delivery systems (ENDS) in conjunction with harm-reduction counseling. Interventionists embody a compassionate, advocacy-oriented "heart-set" or style and deliver manualized components that include a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. The proposed study will feature a randomized controlled trial (N=94) of HaRTS-TRENDS among smokers with lived experience of chronic homelessness who have moved into permanent, supportive housing. Participants will be randomized to receive HaRTS-TRENDS or standard care. The standard care, which is what people most commonly receive from providers, is brief advice to quit plus referral to the Washington State quitline where participants have access to free NRT. All participants will be assessed at baseline and posttest as well as at 1-, 3-, 6-, and 12-month follow-ups. Analyses will be conducted to test the efficacy of HaRTS-TRENDS compared to SC in a) facilitating biochemically verified nonsmoking and b) reducing smoking-related harm as measured by concentration of urinary tobacco-specific nitrosamines (TSNAs). It is hypothesized that, compared to SC participants, HaRTS-TRENDS participants will show a significantly greater likelihood of nonsmoking and reduced concentration of TSNAs. Further, we will examine reductions in smoking craving as a mediator of the HaRTS-TRENDS effect on nonsmoking as well as nonsmoking as a mediator of the HaRTS-TRENDS effect on TSNA concentration. If its results are positive, this project will lay the groundwork for longer-term objectives including dissemination of HaRTS-TRENDS to researchers, clinicians, and community-based agencies to decrease smoking-related harm for a high-cost and severely affected population.
The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to composition in solid medicinal form eliciting anti-inflammatory activity. Invention proposes composition containing 4-hydroxy-2-methyl-3-[N-(2-pyridinyl)-carboxamide] -2H-1,2-benzothiazine-1,1-dioxide and magnesium stearate and microcrystalline cellulose or lactose and starch or aerosil, or magnesium or calcium stearate, or polyethylene glycol 4000 (PEG 4000) as additional accessory substances taken in the ratio given in the invention claim. Composition comprises envelope consisting of acetylphthalyl cellulose, ethyl alcohol, chloroform, dye tropeolin-0 or acid red 2C and vaseline or sunflower oil. Invention provides making tablets with rational vehicles and accessory substances enhancing anti-inflammatory activity and decreasing ulcerogenic effect. EFFECT: valuable medicinal properties of composition. 2 cl
Which isoforms of apolipoprotein E (apoE) we inherit determine our risk of developing late-onset Alzheimer's Disease (AD), but the mechanism underlying this link is poorly understood. In particular, the relevance of direct interactions between apoE and amyloid-β (Aβ) remains controversial. Here, single-molecule imaging shows that all isoforms of apoE associate with Aβ in the early stages of aggregation and then fall away as fibrillation happens. ApoE-Aβ co-aggregates account for ~50% of the mass of diffusible Aβ aggregates detected in the frontal cortices of homozygotes with the higher-risk APOE4 gene. We show how dynamic interactions between apoE and Aβ tune disease-related functions of Aβ aggregates throughout the course of aggregation. Our results connect inherited APOE genotype with the risk of developing AD by demonstrating how, in an isoform- and lipidation-specific way, apoE modulates the aggregation, clearance and toxicity of Aβ. Selectively removing non-lipidated apoE4-Aβ co-aggregates enhances clearance of toxic Aβ by glial cells, and reduces secretion of inflammatory markers and membrane damage, demonstrating a clear path to AD therapeutics.
The tumor microenvironment (TME) profoundly influences tumorigenesis, with gene expression in the breast TME capable of predicting clinical outcomes. The TME is complex and includes distinct cancer-associated fibroblast (CAF) subtypes whose contribution to tumorigenesis remains unclear. Here, we identify a subset of myofibroblast CAFs (myCAF) that are senescent (senCAF) in mouse and human breast tumors. Utilizing the MMTV-PyMT;INK-ATTAC (INK) mouse model, we found that senCAF-secreted extracellular matrix specifically limits natural killer (NK) cell cytotoxicity to promote tumor growth. Genetic or pharmacologic senCAF elimination unleashes NK cell killing, restricting tumor growth. Finally, we show that senCAFs are present in HER2+, ER+, and triple-negative breast cancer and in ductal carcinoma in situ (DCIS) where they predict tumor recurrence. Together, these findings demonstrate that senCAFs are potently tumor promoting and raise the possibility that targeting them by senolytic therapy could restrain breast cancer development. Significance: senCAFs limit NK cell-mediated killing, thereby contributing to breast cancer progression. Thus, targeting senCAFs could be a clinically viable approach to limit tumor progression. See related article by Belle et al., p. 1324.
NEW MATERIAL:A compound shown by formula I (Y is H, OH, group shown by formula II, double line is double bond when Y is H and single bond when Y is other group). EXAMPLE:3-(2,2,3R-Trimethyl-6-methylenecyclohexyl)acrylonitrile. USE:A synthetic intermediate for alpha- or beta-irones. Useful as durable fragrance and flavor imparter or modifier. PREPARATION:(+)-Citronellic acid alkyl ester shown by formula III (R<a> is alkyl) as a starting substance is successively reacted and derived into a 3-(2,2,3R- trinethyl-6-methylenecyclohexyl)-2-phenylselenylpropionitrile shown by formula IV. Then the compound is reacted with hydrogen peroxide in the presence of a base in an organic solvent at 0-50 deg.C to give a compound shown by formula I.
The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
BACKGROUND: Liver transplantation (LTx) constitutes a major life-saving routine treatment for children with end-stage liver disease. However, the analysis of LTx registries in children provides much information about changes in the indication profiles in the recent years.
METHODS: The article provides a comprehensive review about the successes, hopes, and challenges related to changing indications for LTx in children based on the literature review and our own experience. Retrospective review of the indications for LTx at a tertiary referral pediatric hospital was also presented.
RESULTS AND CONCLUSIONS: In the context of the new therapies that have emerged, the need for LTx has decreased in patients with chronic hepatitis B and C infection and tyrosinemia type 1. In primary hyperoxaluria type 1, new RNAi-based therapy has eliminated the requirement for LTx (both isolated or combined). There is a hope that introduction of ileal bile acid transporter (IBAT) blockers reduces the need for LTx in patients with Alagille syndrome or progressive familial intrahepatic cholestasis. The number of children qualified for LTx with urea cycle disorders (UCDs) as a prophylaxis of neurodevelopmental impairment is increasing.
PURPOSE:To obtain a preventive for dermatic inflammation effective for suppressing pimple, spot, freckles, eruption, chapping, heat rushes, cracks, chaps, sunburn, etc., by using a deacetylated chitin having antiinflammatory action as an active component. CONSTITUTION:The objective dermatic inflammation preventing agent contains a deacetylated chitin produced by the alkali treatment of chitin. The agent can be used in the form of ointment, cream, pack and liquid, especially preferably ointment or cream. The amount of the deacetylated chitin is preferably 1-15wt.%. The agent is especially effective for the treatment of pimple. It has extremely excellent effect and is free from side effect.
Myelodysplastic Syndromes (MDS), which includes a diverse group of bone marrow disorders that result in ineffective production of blood cells, frequently occurs in elderly patients. Historically, the available treatments for MDS have been symptomatic and supportive, and have not been shown to be effective in producing sustained improvement in hematopoiesis (production of all types of blood cells ) or in delaying leukemic evolution (leukemia is a serious disease in which too many white blood cells are produced, causing weakness and sometimes death). This project is an open-label (all people involved know the identity of the intervention), multicenter, international single arm, Phase 3b study to provide expanded access to Decitabine for patients with myelodysplastic syndromes (MDS). The purpose of this study is to provide Decitabine to patients with Myelodysplastic syndrome (MDS) according some medical classifications: FAB (French-American-British) subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups, including previously treated and untreated for MDS. The secondary objectives are to evaluate the safety and tolerability of Decitabine, as well as the overall response rate according to the International Working Group (IWG) 2000 and IWG 2006 response criteria, hematologic improvement, cytogenetic response rates (evaluation based on genetic), time to acute myeloid leukemia progression or death (evaluate the length of time that passes prior to onset of leukemia progression and/or death), blood product transfusion requirements per patient (with corresponding dates to collect the number of transfusion independent days), days in the hospital (including reason for hospitalization and the ward within the hospital where the hospitalizations occur) and, optionally, quality of life assessment (EORTC QLQ C-30). 3-day cycle: Decitabine will be administered as a 15mg/m2 administered by continuous infusion over 3 hours repeated every 8 hours for 3 days. 5-day cycle: Another optional schedule could be adopted (at discretion of investigators), Decitabine at a dose of 20mg/m² administered intravenously over 1 hour, once daily for 5 consecutive days, of a 4-week cycle. Treatment may be continued as long as the patient continues to benefit.
All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
Patients had The fixation method that involved creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel. If necessary, the plate was contoured to match the clavicle's shape, with careful consideration given to the appropriate depth of the hook. Dynamic compression was utilized to secure the plate in place. Following surgery, the shoulder was supported with a triangular sling for a period ranging from 2 to 4 weeks. Mobilization commenced at the earliest opportunity, typically resulting in full range of motion within three to four weeks. It is worth mentioning that across both groups, heavy manual labor was prohibited until evidence of solid fracture union was observed.
OBJECTIVES: The aim is to evaluate the prevention and development of cervical cancer in systemic lupus erythematosus (SLE) patients in Japan and its background based on a questionnaire survey.
METHODS: The questionnaire was handed to 460 adult female SLE patients at 12 medical institutions. The participants were grouped by age, and data related to their human papillomavirus vaccination status, age at first coitus, cervical cancer screening, and diagnosis of cervical cancer were analysed.
RESULTS: A total of 320 responses were received. Patients aged 35-54 years included a higher proportion of patients whose age at first coitus was <20 years. This group also showed a higher rate of cervical cancer/dysplasia. Only nine patients had a human papillomavirus vaccination history. Adequate frequency of cervical cancer screening was slightly higher (52.1%) among SLE patients than in the Japanese general population. However, 23% of the patients had never undergone examination, primarily because of a feeling of troublesome. The incidence of cervical cancer was significantly higher among SLE patients. One reason for this may be associated with the use of immunosuppressants, although the difference was not significant.
CONCLUSIONS: SLE patients are at a higher risk of cervical cancer and dysplasia. Rheumatologists should proactively recommend vaccination and screening examinations for SLE female patients.
A case-control study (n=150) will evaluate the clinical utility of the Congo Red test GV-005 in following women with a clinical diagnosis of preeclampsia and clinically healthy women in the postpartum period. Women with preeclampsia (n=100) (cases) and clinically healthy women (n=50)(controls) who are hospitalized postpartum will be recruited for the trial. All women will be asked to provide a urine sample. Samples will be collected daily during a woman's hospitalization. The Congo Red test GV-005 and a standard urine dipstick proteinuria test will be performed by a lab technician within 72 hours of sample collection. The purpose of this research is to evaluate progression of urine congophilia postpartum by following patients diagnosed with preeclampsia and clinically healthy women.
The invention belongs to the technical field of Chinese herbal medicine atomized products, and discloses a herbal atomized composition for improving memory and a preparation method thereof. The composition is prepared from pure plant Chinese herbal medicines, is pungent in taste and warm in nature; the spleen and kidney meridians are the therapeutic principles. Fructus Alpinae Oxyphyllae can improve memory; the black sesame can tonify essence and blood; radix polygonati officinalis improves mental activities; rhizoma Gastrodiae can extinguish wind and stop spasm; folium Eucommiae is effective in nourishing liver and kidney, and strengthening tendons and bones; cornus officinalis astringes and astringes; american ginseng tonifies qi and nourishes yin; the astragalus root has the functions of tonifying spleen and strengthening middle warmer; ganoderma lucidum can tonify qi and tranquilize mind. The prescription is an integral prescription, and after the prescription is combined, the prescription is beneficial to developing intelligence, refreshing brain, improving and improving memory, tonifying essence and blood and improving mental activities. Therefore, the safety is realized, and the uncomfortable feeling is avoided. In the preparation process of the composition, the extract is purified by using a macroporous adsorption resin chromatographic column, so that impurities with different properties can be removed, the purity and content of active ingredients in the extract are improved, and the efficacy of the medicine is improved.
Heterogeneous nuclear ribonucleoprotein U (hnRNPU) is known to play multiple biological roles by regulating transcriptional expression, RNA splicing, RNA stability, and chromatin structure in a tissue-dependent manner. The role of hnRNPU in skeletal muscle development and maintenance has not been previously evaluated. In this study, skeletal muscle specific hnRNPU knock out mice is utilized and evaluated skeletal muscle mass and immune cell infiltration through development. By 4 weeks, muscle-specific hnRNPU knockout mice revealed Ly6C+ monocyte infiltration into skeletal muscle, which preceded muscle atrophy. Canonical NF-kB signaling is activated in a myofiber-autonomous manner with hnRNPU repression. Inducible hnRNPU skeletal muscle knockout mice further demonstrated that deletion of hnRNPU in adulthood is sufficient to cause muscle atrophy, suggesting that hnRNPU's role in muscle maintenance is not during development alone. Treatment with salirasib, to inhibit proliferation of immune cells, prevents muscle atrophy in muscle-specific hnRNPU knock out mice, indicating that immune cell infiltration plays causal role in muscle atrophy of hnRNPU knock out mice. Overall, the findings suggest that loss of hnRNPU triggers muscle inflammation and activates NF-κB signaling in a cell-autonomous manner, culminating in muscle atrophy.
The present invention provides an immersive and multi-posture rehabilitation training system with active/passive physical coordination, including: a lower extremity training mechanism with the first bearing section and lower extremity exoskeleton apparatus. The end of the lower extremity exoskeleton apparatus is pivoted an ankle joint mechanism. An upper extremity training mechanism with a second bearing section which is pivoted on the first bearing section. The second bearing section sets an upper extremity mechanism. A pose adjusting mechanism, which is pivoted on the top of a base, sets at least a slide rail. The first bearing section is correspondingly slid on the slide rail. Therefore, patients can conduct rehabilitation training in decubitus position, sitting position and standing position. An information management system can also be equipped to connect foot pressure sensing module, electrophysiological sensing module, electroencephalographic sensing module, interactive augmented reality device and posture sensing device. The present invention is provided with virtual reality, augmented reality, motor imagery brain-computer interface and multiple source sensing, which provides single or combined immersive augmented reality training that simultaneously satisfies different requirements of training postures from different patients at early stage of rehabilitation (flaccidity stage), middle stage of rehabilitation (spasm stage), and late stage of rehabilitation (convalescence). The rehabilitation training system achieves coordinate exercise of upper and lower extremity to be conducive to ameliorating physical disability, improving the quality of patients' life and easing the burden on the family of patients. Besides, it can be conducive to the development of social welfare and care system; and reduces stress of social development and the country's economy.
The peptidic compounds, R-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-X-(biotin)-NH2 wherein R is the residue of a carboxylic acid and X is a cysteine or lysine residue, analogs thereof, and the biologically and pharmaceutically acceptable salts thereof, contain the 9-amino acid sequence from the basic domain of the Tat protein responsible for specific interaction with TAR RNA, or an analog thereof. The cysteine or lysine residue provides an attachment site for biotin which acts as a cellular uptake enhancer. These peptides bind a fragment of TAR RNA (ΔTAR) avidly and specifically, as measured in an electrophoretic gel shift assay. Further, they inhibit tat gene-induced expression of a stably transfected CAT (chloramphenicol acety transferase) reporter gene linked to the HIV-1 LTR in a model cell assay, but do not inhibit phorbol ester-induced expression of CAT, thereby demonstrating a Tat-dependent mechanism of inhibition. Inhibition of HIV-1 replication after acute infection of MT2 cells was demonstrated by absence of HIV-induced syncytium formation and cytotoxicity, as well as by suppression of reverse transcriptase production. These results indicate that these peptides are capable of competing with the TAR RNA-binding domain of Tat protein and thus are useful as therapeutic agents in the treatment of AIDS.